New Short-Course malaria treatment could prevent relapse
NCT ID NCT05874271
First seen Nov 21, 2025 · Last updated Jun 19, 2026 · Updated 22 times
Summary
This study tested a new way to treat vivax malaria, a type that can hide in the liver and come back. Researchers gave patients a quick G6PD test to check for a genetic condition that can cause dangerous side effects from the drug primaquine. Then they used a high-dose, short-course primaquine regimen tailored to each patient's G6PD level. The goal was to see if this approach is safe, practical, and helps patients complete treatment. Over 790 people with vivax malaria took part in health centers in Papua New Guinea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIVAX MALARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baro Clinic
Vanimo, Sandaun Province, Papua New Guinea
-
Mugil Health Centre
Madang, Madang Province, Papua New Guinea
-
Napapar Health Centre
Kokopo, East New Britain Province, Papua New Guinea
-
Wirui Clinic
Wewak, East Sepik Province, Papua New Guinea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
primaquine
What this could lead to
If successful, this approach could make radical cure of vivax malaria safer and more practical, reducing relapse rates in endemic areas.
What could go wrong
The study is a feasibility trial, not a large efficacy trial, so results may not confirm long-term benefits. Risks include haemolysis in G6PD-deficient patients despite testing.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.